Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesús G. Berdeja, Sundar Jagannath, Muhammad Akram et al.|The Lancet|2021Cited by 1.7k
CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple MyelomaSimon J. Harrison, Piers Blombery, Tamia Nguyen et al.|Blood|2023Cited by 99
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple MyelomaDeepu Madduri, Thomas Martin, Jesús G. Berdeja et al.|Blood|2020Cited by 94
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.Jesús G. Berdeja, Sundar Jagannath, Deepu Madduri et al.|Journal of Clinical Oncology|2020Cited by 78
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory MyelomaSimon J. Harrison, Piers Blombery, Cyrille Touzeau et al.|New England Journal of Medicine|2025Cited by 58